257292-29-8
257292-29-8 structure
- Name: KF38789
- Chemical Name: KF 38789,3-[7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-1,4-thiazepin-5-yl]-4-hydroxy-6-methyl-2H-pyran-2-one
- CAS Number: 257292-29-8
- Molecular Formula: C19H21NO5S
- Molecular Weight: 375.43900
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2017-12-12 21:04:52
- Modify Date: 2025-08-25 16:56:16
-
KF38789 is a selective inhibitor of P-selectin-PSGL-1 binding. KF38789 inhibits the binding of U937 cells to immobilized P-selectin immunoglobulin G chimeric protein (P-selectin-Ig) with an IC50 value of 1.97 μM[1].
| Name | KF 38789,3-[7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-1,4-thiazepin-5-yl]-4-hydroxy-6-methyl-2H-pyran-2-one |
|---|---|
| Synonyms | MFCD00543709 |
| Description | KF38789 is a selective inhibitor of P-selectin-PSGL-1 binding. KF38789 inhibits the binding of U937 cells to immobilized P-selectin immunoglobulin G chimeric protein (P-selectin-Ig) with an IC50 value of 1.97 μM[1]. |
|---|---|
| Related Catalog | |
| In Vitro | KF38789 inhibits P-selectin-induced superoxide production from human polymorphonuclear cells. Intravenously injected KF38789 significantly inhibits the thioglycollate (TG)-induced accumulation of leukocytes in the mouse peritoneal cavity[1]. KF38789 displays a concentration-dependent inhibition of U937 cell adhesion to immobilized P-selectin-Ig with an IC50 value of 1.97±0.74 μM[1]. KF38789 specifically inhibits P-selectin-dependent cell adhesion and the leukocyte recruitment in mouse peritonitis[1]. KF38789 (5 μM) significantly reduces closure of a 500-μm gap between confluent sheets of Human corneal epithelial (HCE)-T cells over an 8-hr period (by ∼40%)[2]. Corneal epithelial cell migration is reduced in the presence of KF38789 (5 μM) [2]. |
| In Vivo | KF38789 can block P-selectin-mediated binding in vitro and leukocyte accumulation in vivo[1]. Intraperitoneal injection of the P-selectin inhibitor KF38789 (daily intraperitoneal injection of 10mg/kg for 12 days) significantly reduces mechanical allodynia in the facial carrageenan-injected mice[3]. Animal Model: BALB/c mice[1] Dosage: 1 mg/kg Administration: Intravenously administrated Result: Significantly reduced leukocyte accumulation. Animal Model: Twenty-four adult male C57BL/6J (B6) mice, about 6-8 weeks of age and weighing approximately 20-30 g[3] Dosage: 10 mg/kg, 1 mg/kg, 0.1 mg/kg, 0.01 mg/kg or 0.001 mg/kg Administration: Intraperitoneal injection daily for 12 days Result: Significantly reduced mechanical allodynia in the facial carrageenan-injected mice. |
| References |
| Density | 1.265g/cm3 |
|---|---|
| Boiling Point | 569.5ºC at 760mmHg |
| Molecular Formula | C19H21NO5S |
| Molecular Weight | 375.43900 |
| Exact Mass | 375.11400 |
| PSA | 106.56000 |
| LogP | 2.77390 |
| Vapour Pressure | 5.54E-13mmHg at 25°C |
| Index of Refraction | 1.583 |
| Storage condition | 2-8°C |